Clicky

Ipsen SA(IPN) News

Date Title
Jul 24 Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
Jul 24 Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors
Jul 23 Ipsen announces changes to its Executive Committee
Jul 22 IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2025
Jul 17 GSK’s Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights
Jul 16 IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2025
Jul 10 Ipsen - June 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
Jun 20 Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors
Jun 17 IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2025
Jun 13 IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2025
Jun 12 Ipsen - May 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
Feb 14 Ipsen SA (IPSEF) Full Year 2024 Earnings Call Highlights: Strong Sales Growth and Strategic ...
Feb 13 Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025
Oct 14 Ipsen receives its second Shingo Prize for operational excellence
Oct 9 Ipsen SA (IPSEF) (H1 2024) Earnings Call Highlights: Strong Sales Growth Amidst Challenges
Oct 9 Ipsen - September 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
Jul 26 Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases
Jul 25 Ipsen outlines $461m for ex-US rights to Day One’s glioma therapy
Jul 25 Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance
Jul 25 Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor